Decoding female physiology: a scoping review on the use of digital health tools to improve women's health and performance

Sarah C Johnson[1,3*], Johanna O'Day[1*], Emily Kraus[2], Scott Delp[1,3], Jennifer Hicks[1,3]

[1]Wu Tsai Human Performance Alliance, Stanford University
[2]The Division of Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Stanford University
[3]Department of Bioengineering, Stanford University
[*]Equal Contributors

Abstract

The increasing adoption of digital health tools by women offers a unique opportunity to characterize biometrics across the menstrual cycle and through menopause, and to understand interactions of biometrics with sleep, physical activity, physiology, and symptoms. This understanding is a vital first step toward solutions to manage symptoms and optimize health. We conducted a scoping review of research using digital health tools like wearables or smartphone applications to characterize physiology, sleep, physical activity, and symptoms throughout the menstrual cycle, perimenopause, and menopause. We summarize the knowledge gained from 36 original research articles. We then report capabilities and accuracies of commercial wearables for measuring biometrics. Finally, we discuss future research needs, including understanding physiological changes during perimenopause, and the role of health behaviours in symptom management. We hope this review will help researchers to fill knowledge gaps to improve wellbeing and performance of women throughout the menstrual cycle and the lifespan.

1. Introduction

Women experience hormonal fluctuations throughout the menstrual cycle and across the lifespan. But there is a lack of tools to effectively manage associated symptoms and optimize wellbeing, athletic performance, and productivity. Between 75 and 90% of women report menstrual symptoms ranging from mild to severe[1,2], with 20 to 40% estimated to experience a more severe premenstrual syndrome[2]. Furthermore 3 to 8% of all women report severe and disabling premenstrual symptoms that meet the criteria for premenstrual dysphoric disorder (PMDD)[2,3].

The impacts from menstrual cycle symptoms are high. For example, in a study of over 32,000 women, 81% reported impaired work performance in the past three months due to the menstrual cycle, and 15% reported absenteeism in the past six months[4]. In Japan, the estimated annual economic burden due to menstrual symptoms was estimated at 8.6 billion United States Dollars[1]. Across a range of sports, more than 50% of female athletes reported a

39 negative impact of the menstrual cycle on training and competition[5–7]. Meanwhile, work days
40 lost due to menopausal transition (perimenopause) symptoms cost the United States $1.8 billion
41 annually[8].
42
Findings from lab studies have identified some connections between physiological measures,
underlying hormonal changes, and symptoms. During the menstrual cycle, the follicular phase is
characterized by rising estrogen levels culminating in a peak just before ovulation, while the
luteal phase is defined by high concentrations of both progesterone and estrogen following egg
release. Many contraceptives involve receiving hormones exogenously, and perimenopause is
characterised by pronounced estrogen fluctuations before permanent decline. Lab studies have
shown that progesterone consistently elevates core body temperature across various female
cohorts[9–11]. This effect, consistent with the observed high progesterone and higher core
temperature in the luteal phase, appears to be reduced by estrogen[10]. During the luteal phase,
heart rate also increases, potentially due to the influence of progesterone and estrogen on the
autonomic nervous system or as a secondary effect of elevated body temperature[12].
Progesterone increases respiratory function by increasing carbon dioxide sensitivity, breathing
rate, and potentially bronchodilation via smooth muscle relaxation, while evidence of estrogen's
interaction on this effect is contradictory[13,14]. Understanding links between symptoms and
physiology is limited, but several lab-based studies suggest that women with severe
premenstrual symptoms or PMDD often exhibit lower heart rate variability (HRV), indicating
reduced parasympathetic activity, at different times in the menstrual cycle[15–18]. While these
findings are valuable, our knowledge of the relationships between hormones, physiology,
symptoms, and health behaviours is still limited.
62
Advances in digital health tools, including wearable technology and smartphone apps, provide a
unique opportunity to bridge critical knowledge gaps in female health, wellbeing, and
performance by enabling large-scale, continuous, and cost-effective collection of physiological
and behavioral data. In-lab approaches, while valuable, have been limited by sample size and
diversity, measurement frequency, and a lack of accompanying physical activity and sleep data.
Wearables can continuously measure heart rate, HRV, skin temperature, sleep metrics, and
activity metrics, while independent or associated smartphone apps allow users to record
menses dates, daily symptoms, mental state, and additional activity and behaviour details. To
effectively apply this technology in studies to improve female health, researchers need to better
understand the capabilities, strengths, and limitations of digital health tools in measuring
physiology and behavior across the menstrual cycle and lifespan.
74
Previous reviews of digital health tools in women's health have focused on identifying unmet
needs in software design and hardware development[19–21], the impact of their use[22,23] and
predicting ovulation and menstruation[20,24–26]. We found only one review that summarised
findings from passive monitoring with commercial wearables or analysis of large datasets, but
this review focused solely on trends in thermoregulation relevant to the menstrual cycle[12]. No
existing reviews summarize findings from digital health tools that concurrently track the
menstrual cycle or menopausal transition and report physiological, behavioural, and/or
symptomatic outputs.

We conducted a scoping review of digital health studies focused on women's health and
summarized the insights gained into menstrual cycle physiology, symptoms, and health
behaviors. Our review focuses on menstruating females, including women on hormonal birth
control and women undergoing perimenopause. The review excludes findings regarding
pregnancy and postpartum. We summarize the reported accuracy and resolution of digital
health tools to assist researchers in device selection. We close by discussing key unmet
research needs in female health, wellbeing, and performance that could be addressed using
digital health tools in order to inspire future research.

2. METHODS

2.1 Literature search

Our scoping review adhered to the recommendations outlined in the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses extension for Scoping Reviews guidelines
(https://www.prisma-statement.org/scoping). We searched for articles on Google Scholar, Web
of Science Core Collection, and PubMed through August 14, 2024 with the terms ("menstrual
cycle" OR "menstruation" OR "period tracking") AND ("digital health" OR "wearable technology"
OR "wearable devices" OR "mobile health" OR "smartphone application" OR "app") AND
("scientific" OR "research outcomes" OR "insights" OR "study results" OR "clinical research").
101
We removed duplicates, then two authors (S.J. and J.O.) independently reviewed titles,
abstracts, and keywords of all the retrieved articles. Articles were included if they (i) were written
in English; (ii) involved human participants; (iii) used wearable devices or mobile health apps;
(iv) analyzed female health physiology or biometrics; (v) and provided quantitative data
collected with digital health tools. We excluded dissertations, theses, conference proceedings,
conference abstracts, and reviews. We excluded articles that did not include menstrual tracking
with a digital health tool and/or articles where longitudinal data concurrent with menstrual
tracking was not reported (Figure 1). We excluded reviews as primary articles, but reviewed
reference lists to identify any additional papers that met our criteria. We repeated the process
replacing the first search term with "menopaus*" instead of the menstrual terms.

2.2 Outcome extraction

113 We extracted the following outcomes from the included articles: scientific insights on female
114 health with regard to menstruation and menopause; how menstrual cycle phase was determined
115 (e.g., self report or hormonal testing); and study details including number of participants,
116 menstrual cycles, participant demographics (age, body mass index (BMI), ethnicity), and the
117 digital health tool(s) used in the study.
118

119
120
121 **Figure 1:** PRISMA flow diagram in the search of papers associated with the menstrual cycle. Generated
122 with PRISMA flow diagram[27].

3. RESULTS

3.1 Characteristics of included studies

In total, 38 studies were considered eligible for this scoping review with our findings summarised in (Table 1 and Table 2). Our search terms focused on the menstrual cycle identified 128 original research articles. We screened the abstracts of all articles, screened the full text of 37 articles, and ultimately included 20 of the identified articles in our review. From the references of these identified articles and websites, we extracted an additional 43 papers and included 16 additional articles. Our search for digital health studies of menopause resulted in 11 articles for screening, and only four for inclusion. Study populations ranged from 10 to 19,000,000 female participants, predominantly aged 18 to 55.

3.2 Insight gained into physiology and behaviours accompanying menstruation

Digital health studies have enabled researchers to confirm and refine our understanding of how menstrual cycle physiology varies across lifespan, between demographic groups, and in subgroups of irregularly cycling participants. Research is emerging that connects physiology across the cycle, as measured by digital health tools, with symptoms, physical activity, and sleep, but knowledge is still limited.

141 ***3.2.1 Characterizing and refining normative trends in menstrual cycle length, length of***
142 ***menses, and timing of ovulation***
143
Menstrual cycle length and variability
Understanding typical cycle lengths and variability, both within and between women, is crucial to
distinguish natural variability from underlying health concerns[28]. In clinical practice, it is
considered normal to have a mean menstrual cycle length of 28 days with a 21-35 day range.
Similarly, across the majority of studies we reviewed, the average ovulatory menstrual cycle
was 28-30 days, while menstrual cycles analysed without confirmed ovulation averaged 27-30
days (Table 1). The standard deviation of menstrual cycle length between people varied from
2.3 to 7.2 days and variation within women from cycle to cycle averaged 2.6 to 4.4 days.
However, these values for average length and variability may not be fully representative, since
studies often excluded menstrual conditions and women with shorter or longer cycles than
"normal."
155
156 Three studies of over 10,000 women reported that between 8% and 13% of women had
157 ovulatory menstrual cycle durations outside "normal" ranges (i.e., less than 21-24 days or longer
158 than 35-38 days depending on the study)[29–31]. Furthermore, in a study of 378,000 women, 8% of
159 the women showed cycle-to-cycle variation of 14 days[32], and two studies reported that over
160 19% of women had a >5 day cycle-to-cycle variation[29,30].
161
One study of athletes that did not exclude participants based on cycle length reported a longer
mean menstrual cycle length of 35 days with a 12-day standard deviation, reflecting the
increased incidence of menstrual irregularity in athletic cohorts[33]. A study of women trying to
conceive found that mean cycle length and standard deviation varied dramatically in those with
menstrual conditions. Women with polycystic ovary syndrome (PCOS), hypothyroidism, or both
conditions reported a mean cycle length of 41, 31, and 76 days respectively[34].
168
Length of Menses
Abnormal uterine bleeding can indicate underlying health problems. We found that the mean
duration of bleeding reported by users of digital health apps was shorter than the 7 days
reported in clinical guidelines[35]. Studies consistently reported a 4-5 day bleed length (Table 1),
regardless of whether ovulation was confirmed or if cycles with prolonged bleeding (over 7
days) were included. A study of over 1,000 participants comparing women on any type of
contraceptive pill to those naturally cycling showed no change in cycle length (27.7±1.44 days)
or menses length (4.36±1.09 days)[36].
177
Phase length and ovulation
Accurately identifying ovulation is crucial for conception planning or avoidance. Identifying
changes in phase length can also help to identify shortened luteal phases that may represent
insufficient progesterone production that can impact fertility[37,38]. Digital health studies show that
ovulation may occur later in the cycle than the previously expected 14 days[39]. Seven digital
health studies (Table 1) reported a mean menstrual cycle length of 15 to 17 days with one study
reporting a 10-day range in ovulation day for women with a 28 day cycle[29]. Most studies

reported estimated ovulation via self-reported luteinizing hormone test results, algorithms based
on self-reported basal body temperature and symptoms, or a combination. We found only one
study that used ovarian ultrasound and serum tests to confirm ovulation[40].
188
Studies using digital health tools have also characterized the phases of the menstrual cycle.
Lab-based studies previously reported greater variability in the length of the follicular phase
compared to the luteal phase, indicating delayed ovulation may be the primary driver of longer
menstrual cycle length[41,42]. Studies using digital health tools confirm this finding, with a strong
correlation between overall menstrual cycle length and the follicular phase (r=0.77) but only a
weak correlation with luteal phase (r=0.37)[43,44]. Furthermore in short menstrual cycles, the
follicular to luteal phase ratio stayed constant, but in long ovulatory menstrual cycles (36-50
days) the follicular phase lengthened by 66% with a minimal luteal phase increase (5%)[43,44]. The
luteal phase length stays consistent across age groups despite menstrual cycle length changing
with age (discussed below)[44,45].
199
3.2.2 Differences in menstrual cycle characteristics across demographic groups
Studies using self-reported tracking apps (with or without ovulation tests) confirmed that
menstrual cycle characteristics shift with age and may be influenced by age of menarche. A
study using data reported by US adolescents aged 13-18 in the Clue app (BioWink GmbH)
found that mean menstrual cycle length was longer (32.4±6.8 days) and the odds of highly
variable, short, or long cycles was greater in the first year of menarche compared to six years
post menarche. Furthermore, shorter cycles and increased dysmenorrhea was associated with
earlier menarche onset. From age 18 to 25 digital health studies confirmed no relationship
between age and menstrual cycle length[43], though after age 25, cycle length shortened with age
due to shortening of the follicular phase[43,45,46]. When comparing across the study populations,
the standard deviation for menstrual cycle length remained similar from age 18 to 30, then
increased for individuals over age 30[43] and 40[46,47].
212
BMI is associated with menstrual cycle characteristics. Individuals with a BMI less than 18.5,
tended to show the highest cycle length variation[30] and reported longer bleed periods than those
in the 18.5 to 25 range[43]. Conversely, variability in cycle length increased when BMI was greater
than thresholds of 25.5 to 30 [43,45,47]. At a BMI above 30, cycle length increased with BMI[45,47].
Another study found that the prevalence of infrequent menses was at least 25% higher in those
with a BMI over 30 and prevalence of abnormal bleeding was 18% higher with BMI above 40
(Table 2) [48]. In contrast, one study found changes in phase and cycle length only in those with
BMI over 50[45]. While most studies reviewed did not report ethnicity, those that did
predominantly included participants from the United States, United Kingdom, and Europe with
predominantly White cohorts reported. Despite the sparse data, the use of digital health tools
has begun to show that there are differences in menstrual characteristics across different
ethnicities. For example, Asian and Hispanic participants reported longer and more variable
menstrual cycles[47] and Black participants showed a 33% higher prevalence of infrequent
menses compared to White non-Hispanic women[48].
227
3.2.3 Physiological changes throughout the menstrual cycle

Understanding changes in biometrics such as temperature and heart rate is relevant for a
variety of health and performance applications. For example, characterizing subtle temperature
dynamics around ovulation is important because many proprietary algorithms that aim to detect
the fertile window in near real time rely on detecting the well-characterized temperature rise
around ovulation. Resting heart rate, HRV, and respiratory rate can be indicators of fitness,
recovery, and overall wellbeing, while unexplained changes in these biometrics can indicate
illness and stress. Establishing baselines for biometric fluctuations across the cycle and lifespan
can help women understand whether changes indicate changing health or performance, or are
an expected change across the cycle. The results of digital health studies have reproduced and
confirmed known trends for skin temperature, resting heart rate, and respiratory rate (Figure 2).
The results have also provided new evidence for HRV fluctuations across the menstrual cycle,
improved resolution (i.e. daily rather than weekly) of physiological patterning across the
menstrual cycle, and quantified how these trends change with age (Table 2).
242

Figure 2: Reported changes in biometrics across the menstrual cycle, as recorded with wearables. Biometrics that
have been characterized include a) resting heart rate, b) Heart rate variability (HRV) c) respiratory rate, and d) skin
temperature. Where phases were defined based on time from menses or ovulation, we assumed a 28-day cycle with
ovulation on day 14. Data from longer cycles (35 days; studies noted with *) were normalized to a 28-day cycle.
Resting heart rate is in units of beats per minute. HRV is shown as the root mean square of successive differences
(RMSSD) in milliseconds, either directly reported or calculated from reported percentage change in fluctuation from a
mean. Respiratory rate is breaths per minute at rest. Skin temperature is in degrees Celsius measured at rest.
252

253 *Skin and Basal Body Temperature*

While traditional fertility apps use manually logged basal body temperature, wearable-linked apps utilize real-time data from devices like rings, earpieces, and wristbands. Across multiple wearable studies, skin temperature was reported to be 0.3-0.5°C lower in the follicular phase as compared with the luteal phase (Figure 2d)[49–56]. These ranges are in agreement with past laboratory studies showing core body temperature is 0.3-0.7°C lower in the follicular phase[12,57].

Although laboratory studies previously reported that minimum basal body temperature occurs one or two days before ovulation, or around day 12-14 for a typical 28-day menstrual cycle[58], digital health studies suggest that skin temperature may reach a minimum as early as day 5 of the menstrual cycle. Using wearable data, Goodale et al. and Zhu et al. reported that skin temperature decreased to its lowest point on menstrual cycle day 5 and remained at that level until ovulation[49,53]. Alzueta et al. reported a minimum temperature at ovulation, but this may be due to a lack of measurements between day 5 of the cycle and ovulation[50]. Shilaih et al. found that in 43% of cases the lowest temperature occurred within the five days prior to ovulation, but in 47% of cases the lowest temperature occurred earlier[52]. Taken together, these studies (Table 2) show that temperature decreases post-menses and a minimum temperature occurs somewhere between menses and ovulation, with the exact timepoint varying between women. All studies that separated early and late luteal phase agree on an increase in temperature post ovulation that peaks in the late luteal phase[49,50,53].

Resting Heart Rate
Previous lab studies on the impact of the menstrual cycle on resting heart rate have had mixed results. Some reported an increase in heart rate in the mid luteal phase[59,60]; one found no change across the menstrual cycle[61], and another reported an increase at ovulation only[62]. However, digital health studies, which provide frequent, passive measurement of heart rate usually during detected sleep periods, have consistently shown that average resting heart rate increased from the follicular phase to the luteal phase in naturally cycling women by 2.7-3.9 bpm (Figure 1A)[36,40,49,50,63–66]. Four of the studies with more granular data found that the largest change in resting heart rate occurred mid-cycle, specifically in the 5 days leading up to, and including ovulation when compared to post ovulation. Two studies additionally report that the amplitude of the change in resting heart rate across the cycle becomes smaller with age[36,67].

Respiratory Rate
Digital health studies have shown that respiratory rate changed between 0.3-0.6 breaths per minute across the menstrual cycle, decreasing from menses to the pre-ovulation days, then increasing and peaking in the late luteal phase (Figure 2c) [49,63]. This higher luteal phase respiratory rate is in accordance with past laboratory-based studies showing resting respiratory rate increased by 0.62 breaths per minute in the luteal phase[68].

Heart Rate Variability
A systematic meta-analysis of 37 lab-based studies reported that, despite some contradictory findings, overall, HRV-associated measures in the follicular phase were significantly higher than those in the luteal phase (Schmalenberger et al. 2019). Digital health studies have consistently found a higher HRV in the first half of the menstrual cycle (Figure 2b). These studies also show

HRV decreased in the second half of the menstrual cycle, with the lowest HRV in the late luteal
phase[36,49,50,63,66]. Reported differences between digital health studies are mainly around the
timing of peak HRV, as Sims et al. found a peak in the early follicular phase (including
menses)[63], while Jasinski et al. reported a peak the day after menses (day 5)[36], and Goodale et
al. reported a peak from day 5 to ovulation[49]. Jasinski et al.[36] also found that when using a
generalised linear model, the amplitude of HRV change between phases decreased significantly
with age, mirroring their findings on age-related decline in resting heart rate amplitude.
305
Effects of hormonal contraception on physiology
Use of different types of hormonal contraception can alter the physiological patterns observed
throughout a menstrual cycle, which may influence contraceptive choice. Among women on the
combined contraceptive pill containing both estrogen and progestin, wrist-worn wearables
detected a 2 bpm higher average resting heart rate during the follicular phase[63]. This heart rate
then peaked in the late follicular phase and declined through the rest of the cycle. This is in
contrast with the rise observed throughout the menstrual cycle in naturally cycling women. The
pattern of HRV was also different in those using the combined contraceptive pill. HRV was
lowest in the late follicular phase, then rose through the remainder of the menstrual cycle. This
is in contrast with the decrease in HRV during the luteal phase in naturally cycling women. The
overall range for both heart rate and HRV was smaller in women using the combined
contraceptive pill, though absolute resting heart rate was higher. Despite the differences in
cardiac biometrics, respiratory rate increased across the menstrual cycle in combined
contraceptive pill users, just as observed in naturally cycling women.
320
321 In the same study, women using progestin-only contraception (either oral or intrauterine),
322 showed overall similar trends in HRV, respiratory rate, and resting heart rate to naturally cycling
323 women[63]. In the luteal phase, HRV was slightly elevated and both HRV and respiratory rate
324 returned to baseline levels more slowly.
325
326 In a second study using a wrist-worn wearable, women taking any type of contraceptive pill
327 showed a smaller amplitude of change in resting heart rate and HRV across the menstrual cycle
328 compared to those naturally cycling (0.28 vs 2.73 bpm and 0.51 vs 4.65 ms respectively)[36]. We
329 did not find any studies that reported biometrics for women using specifically hormonal
330 intrauterine devices or other hormonal forms of birth control.
331
332 **3.2.4 Linking physiology and symptoms across the menstrual cycle**
333
Identifying associations between biometrics and symptoms could increase our understanding of
why symptoms occur and aid in both designing and testing the efficacy of interventions. In lab
studies using electrocardiograms, HRV was lower in the luteal phase in women with the most
severe premenstrual symptoms[15,16]. There is limited research using digital health tools that
assess symptoms and physiology together, but initial studies have shown HRV was inversely
associated with self-reported symptoms in women who met the definition of premenstrual
syndrome or PMDD[69] and with decline in premenstrual mood[70].
341

Changes in menstrual cycle characteristics have also been associated with both symptoms and
biometrics. A study assessing 5 million self-reported menstrual cycles found that a cohort of
women with consistently high menstrual cycle length variability were more likely to report
negative symptoms[32]. Another study using a wrist-worn wearable showed that while both
women with irregular and regular menstrual cycles experienced elevated resting heart rate
during the ovulatory phase compared to the menstrual phase, the increase in resting heart rate
was somewhat smaller in women with irregular menstrual cycles (1.8 bpm) than regular
menstrual cycles (2.1 bpm)[64].
350
351 ***3.2.5 Health behaviors across the menstrual cycle***
352
Understanding how sleep and physical activity can interact with the menstrual cycle is of interest
for optimising recovery and performance, but few studies exist to-date. Although some women
self-report sleep disturbances[71,72], most studies using polysomnography (an in-lab test that
records brain waves and movement) showed little to no changes in sleep measures[73]. Studies
using actigraphy (a typically wrist-worn device specifically measuring movement) found a
decline in sleep efficiency in the premenstrual week (n=163) and an interaction with smoking[74].
Actigraphy-based research has also found an interaction between sleep efficiency and
concentrations of estrogen and progesterone metabolites (n=19)[75]. We found one study in our
scoping review assessing sleep and menstrual cycle using a ring which found no difference in
total sleep time, sleep onset latency, wake after sleep onset, and sleep stages across the
menstrual cycle (n = 26), though sleep efficiency was marginally lower in the mid-luteal phase
compared to menses[50].

3.3 Insight gained into physiology and behaviours accompanying
perimenopause

Overall we found scant passively recorded physiological or activity data during perimenopause.
Many of the digital health studies we reviewed set inclusion criteria for menstrual cycle regularity
that removed the irregular cycles that occur around perimenopause. We found only four studies
with menopausal or perimenopausal cohorts. Cunningham et al. found that after age 40-44,
menstrual cycles increased in length and became more variable, and, by age 50 to 55, 55% of
women reported irregular menstrual cycles[46]. Li et al., who excluded cycles <10 and >90 days,
reported similar results with cycle variability increasing 46% in the 45-49 age group and 200% in
the 50+ age group compared to 35-39 year olds[32]. Markovic et al., who included participants
aged 19–90 without excluding for cycle length or age, found that perimenopausal and
menstruating participants had a higher skin temperature than non-menstruating females[76]. The
menstruating participants also had a higher respiratory rate than non-menstruating participants.
Finally, Costeira et al. developed an app to investigate the role of estrogen in COVID protection
and found that premenopausal women exhibited higher COVID protection compared to
postmenopausal women and this effect was stronger for contraceptive pill users [77]. However,
the same protective effect was not seen in postmenopausal women on hormone replacement
therapy.

3.4. Guide to wearables, measured metrics, and associated accuracy

Our literature review revealed good agreement between digital health and lab-based studies, supporting the use of wearables and apps to study menstrual cycle physiology, but continued validation against "gold-standard" techniques is needed. To guide researchers in device selection, the following sections summarise studies that directly compare wearables to gold-standard measurement approaches (Table 3). We searched PubMed, Web of Science, Google Scholar, and company websites for studies and public data regarding the accuracy and precision of the commercial wearables used in the digital health studies we found. This included the Oura ring, WHOOP wristband, Ava bracelet, Garmin watch, Apple watch, Huawei Band 5, and Fitbit wristband. We provide the reported accuracy of skin temperature, resting heart rate, respiratory rate, HRV, and sleep duration. To understand the accuracy of wearable devices in capturing physical activity throughout the day we refer readers to prior reviews[78–80].

Skin Temperature

Lab-based studies show a body temperature change of 0.3-0.7°C across the menstrual cycle[12,57] and 1.1°C during perimenopausal hot flushes based on the gold-standard rectal thermometer[81,82]. The i-Button is a research-grade wireless semiconductor skin-temperature sensor[83] also used as a standard in some validation studies. Many wearables now passively monitor skin temperature using negative temperature coefficient sensors that contain semiconductive materials that decrease their resistance with increasing temperature. Skin temperature is known to systematically present around 2°C lower than core body temperature changes[84], and BMI can impact the absolute value of recordings due to insulation with visceral fat, although magnitude of change remains unchanged[52]. While reported accuracy compared to core body temperature across all wearables is lacking (Table 3), an in-house study of the Oura ring demonstrated a high correlation (r^2 >0.92), including an accuracy of 0.36°C and precision of 0.13°C when compared to skin temperature measured with i-Button monitors[85]. Comparison of skin temperature immediately after wake-up measured with an Oura ring versus oral temperature showed a correlation of r=0.56[51] .

Resting Heart Rate

Studies using gold-standard electrocardiograms (ECGs) have shown that resting heart rate increases by 2.3-3 bpm between the follicular and the luteal phase of the menstrual cycle [59,60], while changes during menopause are unknown. Wearables use photoplethysmography sensors that detect minor variations in the intensity of light transmitted through the skin to estimate changes in blood flow and cardiac activity. In one external study, 6 devices (Apple Watch S6, Garmin Forerunner 245 Music, Polar Vantage V, Oura Ring 2.0, WHOOP 3.0, and Somfit) were tested overnight in 53 participants. Data resolution varied; raw data was obtained for WHOOP and Somfit, while for other devices, only summaries were available. The Garmin app provided pre-sleep instead of nocturnal cardiac data. Compared to ECG, the WHOOP 3.0 device demonstrated an intraclass correlation of 0.99 for nocturnal heart rate, with average over-estimation bias of 0.7±0.8 bpm[86]. Most devices with nocturnal recordings available reported a good intraclass correlation above 0.85 and low bias of less than 2.6 bpm, with the exception being a 0.65 intraclass correlation reported with Somfit (Table 3). The Oura Ring 2.0 showed an

intraclass correlation of 0.85 and overestimation bias of 1.8bpm, but an Oura-sponsored[87] and
an in-house study[88] reported higher r^2 values of 0.99 and smaller mean biases of -0.63 when
compared to ECG. Researchers should be aware that recordings with photoplethysmography
sensors are systematically impacted by BMI and signals can also be impacted by skin tone[89].
Furthermore, when monitoring heart rate during exercise, devices using 2-electrode chest
straps [90] and wearing PPG monitors on the upper arm can be more accurate than wrist-worn
devices [91].
433

Respiratory Rate
In the laboratory, respiratory rate during sleep is measured with belts that sense chest wall
motion or with respiratory inductive plethysmography where coils of wire are placed around the
chest and abdomen[92]. Studies using this approach show that respiratory rate changes across
the menstrual cycle range from 0.63 to 2 breaths/min[68,93]. Wearable devices estimate
respiratory rate using small photoplethysmography sensors on the skin that detect the high-
frequency variations in heart rate linked to respiratory cycles, a feature called respiratory sinus
arrhythmia. We found limited data on wearable accuracy for respiratory rate ([Table 3](#)). One
external study funded by a grant from WHOOP reported no significant difference between
recordings with WHOOP 2.0 and respiratory inductive plethysmography (15.7±1.7 versus
15.6±1.7 breaths/min, respectively), with a mean bias of 0.1 breaths/min (1.8%) and a precision
bias of 1.0 breaths/min (6.7%)[94].
446

Heart Rate Variability (HRV)
In-lab studies use electrocardiograms to record individual heart beats then calculate the
variability in heart beat timing in a number of ways. The most common method reported was
the root mean square of successive differences (RMSSD) between the interbeat intervals over a
sleep or rest period, reported in milliseconds or log-transformed values. A meta-analysis of 37
studies indicated a significant overall decrease in cardiac vagal activity from the follicular to the
luteal phase, but only 2 of 8 studies reported a significant difference in RMSSD in the range of 9
to 20 ms[95–97]. Wearables estimate HRV using heart rate recordings from the
photoplethysmography sensor. The comparative study of Miller et al. found that the WHOOP 3.0
device demonstrated the highest HRV estimation accuracy compared to ECG measures,
underestimating at -4.5±3.9 ms with a 0.99 intraclass correlation[86] . An external study funded by
an Oura grant reported a 0.98 r^2 value and -1.2ms bias when compared to ECG
measurements[87], which is an improved performance from the 0.85 intraclass correlation
reported in the 6 device comparative study[86].
461

Sleep
Polysomnography is the gold standard for measuring sleep in a laboratory[92]. Detection of sleep
using commercial wearable devices typically uses a combination of cardiac metrics such as
resting heart rate, HRV, respiratory rate, and movement metrics. The comparative study of 6
wearables found that all could estimate the sleep-wake sections of sleep throughout the night
with relatively high accuracy (>85%) compared to polysomnography. However, the accuracy in
estimating total sleep time varied widely, with errors on the order of one minute for the Oura ring
and Polar watch, and 40 minutes or more for the Apple Watch and Garmin watch. All six

devices showed low accuracy in identifying the phases of sleep (e.g., deep sleep), reporting
less than 65% agreement with polysomnography[86]. Several other external studies show that
commercial wearable devices tend to overestimate sleep duration. Sleep duration was
overestimated by 15 minutes with the Oura Ring[98], by 56 minutes with the Fitbit[99] and 11
minutes with the AVA bracelet)[100].
475

4. Discussion

Our scoping review reveals several promising contributions of digital health studies to our
understanding of women's health and performance. Studies using digital health tools have
begun to establish detailed, normative data about the menstrual cycle. For example, while skin
temperature is often used to estimate fertile windows, we found that digital health studies
indicate its minimum can occur as early as day five of the menstrual cycle, unlike the 1-2 days
before ovulation reported by lab studies. This knowledge could improve the efficacy of
wearable-based tools for contraception or conception. Digital health studies have also confirmed
fluctuations in resting heart rate and HRV across the menstrual cycle, and discovered a
decrease in the magnitude of this fluctuation with age. Understanding these changes across the
lifespan can help women set realistic training and recovery expectations. In addition, digital
health tools have begun to address how biometric changes are connected to hormone-related
symptoms. For instance, unlike in smaller lab-based studies, studies using data from wearables
found an inverse association with HRV and symptoms (both affective and physiological) in
women with self-reported premenstrual disorder symptoms. This information is needed for
quantifying the effectiveness of symptom-reducing intervention.
492

Despite new data from digital health studies to characterize normative trends, there remains a
need to better understand deviations from the norm, both within and between individuals. In
some cases, whole cohorts have been omitted from most research. For example, most of the
research we reviewed was carried out in predominantly White cohorts and in the United States,
United Kingdom, and Scandinavian countries, which limits our understanding of the
relationships between race, ethnicity, and menstrual cycle physiology. Perimenopausal women
are often omitted from studies, so characterization of normal hormonal fluctuations and
physiological change during perimenopause is lacking. This is reflected by the fact that fewer
than 1 in 10 women in the United Kingdom feel that they have received sufficient advice on what
to expect during perimenopause[101]. Furthermore, we found that many studies focused on
regularly menstruating women, often only including analysis of cycles with estimated ovulation,
and excluding women with conditions impacting menstruation or using hormonal contraceptives.
Menstrual conditions are common; endometriosis affects 10% of women and many women are
undiagnosed for years[102,103]. Although some atypical menstrual cycles may present no health
concerns, identifying and understanding the cause of irregularity and its biometric connections
becomes crucial for better diagnostics and monitoring intervention efficacy. The relative
accessibility and lower cost of digital health tools compared to lab-based approaches offers
promise to including these under-studied cohorts in research.
511

512 Future digital health studies should concurrently measure hormones, biometrics, and symptoms.
513 Understanding their relationships is necessary for managing symptoms and evaluating the
514 effects of hormonal contraception or other treatments. For example, while it is known that
515 fluctuating estrogen levels during perimenopause alters receptor regulation in the brain [104], the
516 mechanism linking these fluctuations to vasomotor symptoms, autonomic dysfunction,
517 neuropsychiatric symptoms, or biometric alterations remains unclear. The physiological impact
518 of hormonal contraception, including effects on cardiovascular biometrics associated with
519 athletic performance, also remains unclear. Initial findings using wearables suggest that heart
520 and respiratory rate is increased in women on combined estrogen and progesterone pills[63] ,
521 contrasting with no differences found in smaller lab studies[105]. For female athletes striving for
522 peak performance, even small physiological changes may be significant, yet women are often
523 left to use trial and error approaches when selecting contraception. Furthermore, we need to
524 understand the timing and characteristics of the transition to a natural hormone cycle after
525 individuals discontinue using hormonal contraception[106]. Using wearables could help to
526 characterize these effects and contribute to informed contraceptive choices.
527
528 Digital health tools can help quantify how behavior and physical or social environment may
529 influence hormones and physiology, enabling the development of tailored guidelines to manage
530 symptoms and optimize performance. For example, can increased sleep in the luteal phase
531 mitigate premenstrual symptoms? Should performance expectations be adjusted based on
532 menstrual phase? Does optimum recovery time differ in different phases of the menstrual cycle?
533 During perimenopause, what behaviors and activity timings are associated with changes in
534 heart rate, night sweats, and disrupted sleep? By understanding how behaviors can mitigate or
535 exacerbate symptoms, women are empowered to manage their health more effectively.
536 Wearables could also serve as intervention tools. For instance, in a pilot study, a mobile app
537 providing HRV biofeedback training showed promise in reducing premenstrual anxiety, stress,
538 and poor sleep[107].
539
540 Researchers selecting digital health tools must consider their cohort, research question, and the
541 limitations of each tool. For instance, self-reports cannot confirm if a menstrual cycle is truly
542 skipped or simply not reported. While biometric data can be used to predict menstrual cycle
543 and/or ovulation occurrence with good accuracy, ovulation can sometimes occur without the
544 typical biometric pattern changes and vice versa. A study of trail runners may require a device
545 with long battery life that measures heart rate and distance with high accuracy and resolution
546 during activity only, while a study focused on recovery may require capturing accurate nocturnal
547 cardiac and sleep parameters with constant daily activity monitoring. Researchers should be
548 aware of limitations when working with technology where the reported accuracy is based on
549 testing with specific populations; for example, photoplethysmography accuracy can vary with
550 skin color and BMI[89]. Furthermore, retrospective studies using passively collected wearable
551 data may contain self-selection bias as individuals who purchase fitness tracking wearables
552 may be more active, of a higher socioeconomic status, and more health conscious than
553 average. However, providing wearable devices to participants and intentionally recruiting
554 diverse populations can help to mitigate this bias.
555

As technology continues to improve, we hope for the development of new tools to monitor hormones, physiology, and behaviour alongside consistent protocols and safe practices. Continuous and minimally invasive monitoring of biomarkers, such as hormones via sweat or interstitial fluid hold promise. Such monitoring could provide insights into normal, optimal, and pathological states, ultimately guiding more effective management of symptoms and health. As research in this field grows, it is important for researchers to establish and use standardized methodologies (e.g., measuring HRV during specific sleep periods versus during the day) and data reporting (e.g., consistent HRV metrics). With the increasing use and development of digital health tools in women's health research, there is also a vital need to address privacy concerns, particularly given the legal complexities surrounding pregnancy termination. Careful consideration must be given to research planning, data handling, and privacy, as discussed in detail elsewhere [108], including specific considerations for female health data and privacy analyses of existing apps[109,110].

Digital health research offers promise in improving our understanding of the interaction of physiology, behaviour, and symptoms during the menstrual cycle and perimenopause. The use of digital health tools in female health is often focused on pregnancy prevention and fertility. By facilitating characterization of healthy menstrual cycle norms across a more diverse group of women, digital health tools can enable understanding of healthy norms and identify when medical evaluation is warranted. Furthermore, integration of biometric monitoring with underlying hormone fluctuations, symptoms, and health behaviors can help to identify targets to monitor interventions and develop healthy biometric ranges. Not only is this understanding a vital first step toward developing effective solutions, but it also empowers women to take ownership of their health and enhance their quality of life.

5. Author Information

Authors and Affiliations

Wu Tsai Human Performance Alliance, Stanford University
Sarah C Johnson[*], Johanna O'Day[*], Scott Delp and Jennifer Hicks.
The Division of Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Stanford University
Emily Kraus
Department of Bioengineering, Stanford University
Sarah C Johnson, Scott Delp and Jennifer Hicks
[*]Equal Contributors

Contributions

595 SCJ, JO, and JH conceived and defined the scope of the review and wrote the manuscript. SCJ
596 and JO carried out the scoping review search and interpreted, collated and processed the data.
597 SCJ, JO, EK, SD and JH reviewed, edited, and approved the final manuscript.

598 Corresponding author

599 Correspondence to Dr SC Johnson at scjohns@stanford.edu

600 Competing interests

601 The authors declare no competing interests.
602

603 6. Acknowledgements

604
605 This study was funded by the Wu Tsai Human Performance Alliance at Stanford University and
606 the Joe and Clara Tsai Foundation. The funder played no role in study design, data collection,
607 analysis and interpretation of data, or the writing of this manuscript. We also thank Dr Alex
608 Gonzalez for his contribution to early conception.
609
610

611 8. Data availability

612 Data sharing is not applicable to this article as no datasets were generated or analysed during
613 the current study.

614 9. Tables

Table 1: Menstrual cycle characteristics recorded with digital health tools.

Ref.	Digital health tool	Cohort size	Age (mean or range)	Ovulation estimation method	Naturally cycling confirmed	Cycle length or other inclusion criteria (days)	Cycle or phase length (days; mean ± SD, unless noted)			Bleed length (days)	Inter-cycle variation (days; mean ± SD, unless noted)
							Cycle	Follicular	Luteal		
43	Natural Cycles	124,648	30	Algorithm with BBT on >50%+ LH if available	Yes	10-90 days	29.3±5	16.9±5.3	12.4±2.4	4.0±1.5	2.6±2.5
111	Kindara	13,674	29	Algorithm + FAM with BBT	Yes	No midcycle bleed, duration ≥4 days more than bleed	28	16 median	12 median		
	Sympto	199,293	29	Algorithm + FAM with BBT	Yes	No midcycle bleed, ovulation detected	28	16 median	13 median		
32	Clue	378,694	21-33	None	Yes	None	29.7±6			4.1±1.8	4.15±4.94
30	Flo	1.5M	18-55	LH test	No, contraceptive pill use included	3 cycles	28 mode	13 mode	15 mode		25% 0 to 1.5 days, 69% <6day
36	WHOOP 3.0/4.0	11,629	35	None	No, contraceptive pill use included	21-35. Bleed ≤7	27.4±2			4.7±1.1	
		9,968	35	None	Yes	21-35. Bleed ≤7	27.4±2			4.7±1.0	
		1,161	31	None	No, only contraceptive pill users	21-35. Bleed ≤7	27.7±1			4.4±1.1	
29	Clearblue connected ovulation test system	1,143	18+	LH test	Yes	Not 50% shorter or longer than baseline	28 mode	mode 15 (27%)			62%±2 in 28 day cycle, 26%≥4, 19%≥5
112	Luna Luna	7,043	33	31% clinical, 54% test kit	Yes	21-45	29.8	14.8 [10-23]	13.91 [10-19]		
113	Ovia	45,360	31±5	None	Yes	Women who conceived within 1 year of tracking	29.8			4.4±4.7	14% had 9-25 day variation

31	Natural Cycles	18,076	33	Algorithm with BBT on 10+ days	Yes	No medical condition that may influence cycle regularity	29.4			4.2 [4.2-4.2]	
114	Clue	6,897	18-40+	None	Yes	Exclude >90, vaccinated group	30±7.3			4.2-4.6±2. If vaccinated on bleed: 5±3	
		662				Exclude >90, unvaccinated group	29.7			4.3±1.6 4.2±1.7	
76	Ava bracelet	179 vaccinated	41±8	Algorithmic: 5 metrics inc skin temp, heart rate	No, any contraceptive users included	> 1 cycle + daily sync	28	16.92	11.02	4.8	
115	Clue	584	26	None	No	24-38. Bleed<9	29			4 median	
		223	24	None	Yes	24-38. Bleed<9	28			5 median	
		40+STI	27	None	No	24-38. Bleed<9	30			4 median	
		18+STI	26	None	Yes	24-38. Bleed<9	28			4 median	
46	Flo	19.2M	18-55	None	Yes	≥10	28.5±3.2			5.2±0.9	4.01±4.74
33	FitrWomen	20 athletes	25±2	None	No, contraceptive users (4) included	At least 1 cycle, mean 10 months	34.9±11.6				
116	Proov	40	35	Urine test kit (4 hormones)	Yes, attempting conception	Had tracked 1 cycle prior to study	No data				
117	Ovia	98,903	18-45	LH test kit	Yes, newly trying conception	≤19 and <60 days	29.6±5.4				
34	Proprietary sensor + vaginal sensor	80	32	Vaginal temperature recordings	Yes, attempting conception	PCOS diagnosis	40.9±30.1				
						Hypothyroid diagnosis	31.2±4				
						PCOS + Hypothyroid diagnosis	76.2±104.8				
						No known diagnosis	35.4±16.6				

FAM - fertility awareness methods; LH - luteinizing hormone test; BBT - basal body temperature; PCOS - Polycystic ovary syndrome; STI - sexually transmitted infection

Table 2: Insights from passive monitoring of menstrual cycles with wearables. Naturally cycling women unless otherwise stated.

Finding	Ref	Biometric Measure	Phase determination	Cohort (n participants, age, n cycles)	Notable additional details
Variables across the cycle					
Resting heart rate increased across the menstrual cycle	63	WHOOP ≤3.0 Strap	Ovulation unconfirmed. 4 equal phases	n=3870, age 34±7 yrs, cycles: 13,535	Mean range of 3 bpm from 55.5 to 58.5bpm with minimum in early follicular phase
	64	Basis Peak, AVA bracelet, PulseOn	Ovulation day estimated with urine test	n=91, age 33±5yrs, cycles: 274 ovulatory	Mean range of 3.8 bpm with minimum in menstrual phase
	49	Ava bracelet	Ovulation detected with urinary LH test	n=193, age 33±4 yrs, cycles: 705 with LH surge	Mean range of 3.91 bpm and minimum in the follicular phase (56.6) instead of the menstrual
	50	Oura (v 2.43.1)	Ovulation estimated via positive LH urine test	n=26, age 24±1 yrs, cycles: 1 ovulatory each	Mean range of 2.7 bpm from 63.3 to 66 with minimum during menses
	36	WHOOP 3.0 or WHOOP 4.0	No confirmed ovulation	n=9968, age 18+	Mean of 60± 8 bpm with amplitude 2.73 bpm ±1.9. Lowest point at day 5 and peak at day 26
	65	Fitbit Inspire 2	Ovulation estimated as 14 days prior to menses	n=33 , age 24±3 yrs, cycles: 50	Mean range of 4bpm from 64 in menses, mean 67±7bpm. 4 contraceptive users.
	66	HRV4Training app	No confirmed ovulation, bisected cycle duration	n=5425, age (all gender) 37±1 yrs, cycles: ≥5 each	Mean 61±8bp. 1.6% increase between follicular and luteal phase. Includes contraceptive use
	40	Huawei Band 5	Ovarian ultrasound and serum testing	n=89 regular, 25 irregular, mean age 31, cycles: 77	Increased from the fertile phase, range 2.7bpm
HRV decreased across the menstrual cycle	66	HRV4Training app	No confirmed ovulation, bisected menstrual cycle	n=5425, age (all gender) 37±12 yrs, cycles: ≥5 each	Daytime RMSSD decreased 3.2% from follicular to luteal phase. Includes contraceptive use
	63	WHOOP ≤3.0	Ovulation unconfirmed. 4 equal phases	n=3870, age 34±7 yrs, cycles: 13,535	Nocturnal RMSSD decreased from 70.1ms with range 6.6ms
	49	Ava bracelet	Ovulation detected with LH urine test	n=193, age 33±4 yrs, cycles: 705 with LH surge	Nocturnal HRV was higher in the follicular and fertile phase. Normalised range +0.16 to - 0.2

	50	Oura v2.43.1	Ovulation estimated via LH urine test	n=26, age 24±1 yrs, cycles: 1 ovulatory each	From menses, nocturnal RMSSD tended, then was lower (p=0.034) in the mid to late luteal phase respectively.
	36	WHOOP 3.0 or 4.0	No confirmed ovulation	n=9968, age 18+	RMMSD peaked at day 5, decreasing to a minimum at day 27 with range 4.65±6.9ms
	40	Huawei Band 5	Ovarian ultrasound + serum	n=89 regular, 25 irregular, mean age 31, cycles: 77	The natural logarithm of SDNN and the low frequency to high frequency ratio decreased and increased respectively from the fertile window
Respiratory rate decreased in the late follicular phase then increased through the luteal phase	63	WHOOP ≤3.0	Ovulation unconfirmed, 4 equal phases	n=3870, age 34±7 yrs, cycles: 13,535	A minimum of 15.9bpm in the late follicular then increases with range 0.3 bpm
	49	Ava bracelet - 2019	Ovulation estimated with LH urine test	n=193, age 33±4 yrs, cycles: 705 with LH surge	Higher in menses/ late luteal phase, lowest in the fertile window (16.4 bpm). Range: 0.64 bpm
Skin temp was lowest in the menstrual or follicular phase than increased to peak in the late luteal phase	49	Ava bracelet - 2019	Ovulation estimated with LH urine test	n=193, age 33±4 yrs, cycles: 705 ovulatory	Minimum in the follicular phase (33.87°C) Total range was 0.45°C. Conception-seeking
	50	Oura v2.43.1	Ovulation estimated via LH urine test	n=26, age 24±1yrs, cycles: 1 ovulatory each	Temperature was 0.01 °C lower during ovulation than menses. Range is 0.32°C
	51	Oura + LH urine kits	Ovulation determined with LH urine test	n=22, age 35±9 yrs, cycles: 2±1 ovulatory each	0.30 °C±0.12 higher in the luteal compared to follicular phase
	52	Ava Bracelet pre 2019	Ovulation determined with LH urine test	n=136, age 33.66±3.86 yrs, cycles: 437 ovulatory	Lowest in follicular phase (35.23°C) not menses, peak in early luteal phase. Range: 0.81°C
	53	Ava Bracelet 2.0	Ovulation determined with LH test	n=57, age 27±4 yrs, cycles: 193, 170 ovulatory	Consistent in the pre-ovulatory phase, higher in the post-ovulatory phase. Range: 0.33-0.50 °C
	54	Luna-Luna app	Ovulation determined with LH test kit and BBT	n=10, age 22±1 yrs	Range: 0.26°C±0.09. The amplitude of change positively correlated with menstrual cycle length
	55	Abdominal sensor	Ovulation with LH test	n=43, age 39±6 yrs, cycles: 100	Changed 0.34C from 36.3±0.3C to 36.7±0.3C
	56	FitbitSense	Mira urine kit and app	n=49, age 18-30 yrs, cycles: 123	Change of 0.3C with low of 33.7±0.8°C in late follicular and peak in luteal of 34.0±1°C

Sleep did not change across the menstrual cycle	50	Oura v2.43.1	Ovulation estimated via LH urine test	n=26, age 24±1 yrs, cycles: 1 ovulatory each	No difference in total sleep time, sleep onset latency, wake after sleep onset and sleep stages. Sleep efficiency was marginally lower in the mid-luteal phase compared with menses
	65	Fitbit Inspire 2	Ovulation estimated as 14 days prior to menses	n=33, age 24±3 years, cycles: 50 ovulatory	No change in sleep between phases. A slight decrease in sleep duration pre-menses. Included 4 contraceptive users
	54	Luna-Luna app	Ovulation determined with LH test	n=10, age 22±1 yrs	Duration stayed consistent. A deep sleep score was higher in early and late follicular phase than menses, the early and late luteal phase
Variables across the cycle in those on hormonal contraception					
Combined pill users show overall higher heart rate with less change across the cycle; different patterns of HRV and respiratory rate change.	63	WHOOP ≤3.0	Ovulation unconfirmed. 4 equal phases	n=3870 naturally cycling, n=455 combined pill users, age 34±7 yrs, cycles: 13,535	Resting heart rate was 2 bpm higher at menses, peaked in the late follicular phase and fell in the late luteal phase unlike the increase in naturally cycling women. Range: 1.5bpm
	36	WHOOP 3.0 or 4.0	N/A	n=9968 naturally cycling n=3322 combined pill users, age 18+	Resting heart rate showed less fluctuation in women on the combined pill compared to those naturally (0.28 vs 2.73 bpm)
	63	WHOOP ≤3.0	Ovulation unconfirmed. 4 equal phases	n=3870 naturally cycling, n=455 combined pill, age 34±7 yrs, cycles: 13,535	HRV decreased from the late follicular phase then rose during the early and late luteal phase unlike the naturally cycling women which decreased throughout the cycle. Range: 2.5ms
					Respiratory rate rose from 16 to 16.2rmp, across the menstrual cycle with an absolute higher value (16 vs 15.9 rpm), and lack of decrease in the late follicular phase, compared to naturally cycling women
Progestin-only users show similar resting heart rates and HRV to naturally cycling women, but increased respiratory rate across	63	WHOOP ≤3.0	Ovulation unconfirmed. Phases set by equally dividing menstrual cycle duration into 4	n=3870 naturally cycling, n=269 progestin-only (pill or IUD not specified) age 33.5±7.3 yrs, cycles: 13,535	Heart rate rose from the early follicular phase to the early and late luteal phase. Range: 2.2bpm
					HRV decreased in the early follicular (71ms) to early luteal phase (65.5ms) but was higher in the late luteal phase (66.5ms). Range: 5.5ms

the menstrual cycle					Respiratory rate increased across the menstrual cycle from 16 to 16.2 rpm but did not decrease in the late follicular state unlike naturally cycling women. Range: 0.2 rpm
Phase length changes with cycle length					
Bleed phase duration changed with very short and long cycles.	43	Natural Cycles app	Ovulation detected algorithmically from self-reported BBT and LH tests when available	n=124,648, age 30.3 yrs, cycles: 612,613+	Ovulatory and non-ovulatory cycles. Very short cycles had shorter bleed lengths by 12%. Very long cycles had longer bleed lengths by 6%
Long ovulatory cycles had proportionally longer follicular phases	43	Natural Cycles app	Ovulation detected algorithmically from self-reported BBT and LH tests when available	n=124,648, age 30.3 yrs, cycles: 612,613+	Ovulatory and anovulatory cycles. Very short 15-20 day cycles had shortened follicular (by 34%) and shortened luteal phases (by 35%). But long 36-50 day ovulatory cycles had 66% longer follicular phases with luteal phase only increasing by 5%
	29	Clearblue connected ovulation test system	Ovulation estimated with LH urine test.	n=32,595, app intended for age 18+, cycles: 75,981	App intended to aid conception. Follicular phase correlated with cycle length (Pearson r=0.77, p<0.001). Luteal phase correlated with cycle length (r=0.37, p<0.001)
Age					
The amplitude of resting heart rate and HRV change decreased with age	36	WHOOP 3.0 or 4.0	N/A	n=9,968 naturally cycling n=3,322 combined pill users, age 18+ yrs	Amplitude change in resting heart rate significantly decreased with age
					Amplitude change in HRV significantly decreased with age
	67	Clue app	Unconfirmed ovulation	n=499,000, age 15-35+ yrs, over ≥12 unique mo.	As age increased, premenstrual effects on resting HR decreased in magnitude (p<0.001)
Premenstrual weight gain was less with age	67	Clue app	Unconfirmed ovulation	n=499,000, age 15-35+ yrs, over: ≥12 unique mo.	Increase in premenstrual weight decreased with age
Premenstrual negative mood rose with age					Premenstrual negative mood effect increased with age from age 15-20 to 30-35

Highly variable, short or long cycles were greater in year 1 post-menarche	118	Clue app	Ovulation not estimated	n=6486, age 13-18 (mean 16), cycles: 38,916	51.5% of people showed variable cycles (<21 or >45 days or bleed phase >8 days). Females <1 year vs 6+ years post-menarche had lighter flow but more highly variable or short cycles
Earlier menarche impacted cycle length and bleeding					Menarche age ≤10 vs 14+ was associated with shorter cycle length, increased odds of dysmenorrhea, and less high cycle variability
Cycles shortened with age then became more variable	46	Flo App	Ovulation not estimated	n=19,266,573, age 18–55 yrs	From age 18-24, cycles were shorter and more variable until age 40-44 when menstrual cycles and menses became longer and more variable
	47	Apple Health App	Ovulation not estimated	n=12,608, age 33.8 yrs, cycles: 165,668	Menstrual cycle length was shorter with age to age 50 then became longer. Cycle variability was smallest age 30-35 then increased 200% age 50+ vs age 35–39 yrs
	43	Natural Cycles app	Ovulation detected algorithmically from self-reported BBT and LH test when available	n=124,648, age 30.3 yrs, cycles: 612,613+	Menstrual cycle length fell from 30 to 27 days from 18 to 45 yrs and cycle variability fell by 0.5 days. Follicular phase shortened only
Luteal phase length was stable with age	30	Flo app	Ovulation determined with LH test	n=1,579,819, age 18+ years, cycles: 1-31+ each	Luteal phase remained 15 days across ages in this cohort not using oral contraceptives
BMI					
High BMI was associated with altered menstrual characteristics	43	Natural cycles	Ovulation detected algorithmically from self-reported BBT and LH test when available	n=124,648, age 30.3 yrs, cycles: 612,613+	In ovulatory cycles BMI > 35 showed 0.4 day higher variability
	30	Flo app	Ovulation determined with LH test	n=1,579,819, age 18+ yrs, cycles: 1-31+ each	Altered median cycle length, follicular phase and luteal phase length with BMI>50 only.
	47	Apple Health app	Ovulation not estimated	n=12,608, age 33±8 yrs cycles: 165,668	The menstrual cycles in participants with BMI 30 to <35, 35 to 40 and ≥40 were 0.3, 0.5 and 1.5 days longer respectively. With BMI>25.5 there was also more cycle variability

	48	Apple Health app	Ovulation not estimated	n=18,875, age 33±8.2 yrs, cycles: 16 ±9 each	Prevalence of infrequent menses increased in BMI>30,>35 and >40 by 31,25 and 51%. Those with BMI > 40 also had an 18% higher prevalence of abnormal bleeding
Low BMI associated with highest cycle variability	30	Flo app	Ovulation determined with LH test	n=1.5m, age 18+, cycles: 1-31 each	No oral contraceptive use. Women with the lowest BMI showed the most cycle length variation
HRV change altered with BMI	36	WHOOP 3.0 or 4.0	N/A	n= 9968, age 18+, mean 35 yrs	As BMI increased, so did amplitude of HRV change with menstrual cycle
Ethnicity					
Ethnicity was associated with differences in cycle length, cycle length infrequent menses prevalence	47	Apple health app	Undetermined	n=12,608, age 33±8 yrs, cycles: 165,668	Menstrual cycles were 1.6 days longer for Asian and 0.7 days longer for Hispanic participants with more cycle variability compared to white non-Hispanic participants. No difference was seen with Black participants
	48	Apple health app	Undetermined	n=18,875, age 33±8.2 yrs, cycles: 16±9 cycles	Black participants had a 33% higher prevalence of infrequent menses compared to White non-Hispanics after controlling for age and BMI
Irregular cycles					
Irregular cycles associated with more negative symptoms and less change in heart rate	32	Clue app	Ovulation not estimated	n = 378,694, age 21–33 yrs, cycles: 4.9M	Varying menstrual cycle length associated with specifically headaches and tender breasts
	64	AVA bracelet, PulseOn, Basis Peak	Ovulation day estimated with urine test	n = 91, age 33.2±4.7 yrs, cycles: 274 ovulatory	Irregular cycles showed less resting heart rate change between ovulation and the luteal phase (1.8 vs 2.1 bpm) and luteal to menstrual phase
Irregular cycles were most common at 51-55 yrs	46	Flo App	Ovulation not estimated.	n=19,266,573, age 18–55 yrs	Irregularity was highest in age 51–55 (44.7%), and lowest in age 36–40 (28.3%)
In healthy cohorts, 8% showed abnormal	31	Natural cycles app	Algorithmic ovulation prediction, self reported	n=18,076, age 33, cycles: 214,426	8.7-8% show abnormal cycle length (< 24 or > 38 days, and menses >8 days)

cycle length, 2.5% showed anovulation			BBT		Anovulation in 2.9% to 2.5% of cycles
Ovulation was not indicative of ovulatory function	116	Proov app	Urine tests for LH, FSH, estrogen & progesterone metabolites	n=40, age 34, cycles:40	38/40 cycles ovulatory (LH and progesterone rise) but only 22/40 had sustained progesterone rise indicative of ovulatory function.
Abnormal uterine bleeding observed in 17% of naturally cycling women and was associated with menstrual conditions	48	Apple Health Survey	Ovulation not estimated	n=18,875, age 33±8.2, cycles: 16±9 each	Of the 17%, 2.9% had irregular menses, 8.4% infrequent menses, 2.3% prolonged bleeding and 6.1% intermenstrual bleeding
					Bleeding was increased in women with PCOS (+19%), hyperthyroidism (+34%), hypothyroidism (+17%), endometriosis (+28%), cervical dysplasia (+20%) and fibroids (+14%)
Symptoms, Mood and Physiology					
HRV metrics inversely associated with PMD symptoms and mood and decreased more with more severe diagnosis	69	Huawei Fitness Tracker 6 Pro	N/A	n=193 (68 prospectively confirmed PMDs), age: 20±2 yrs, cycles: 293	In women with PMDs, nocturnal HRV metrics pre and post menses were inversely associated with symptoms, particularly the affective
					Women with PMDs showed more HRV change in the premenstrual week compared to those with only premenstrual syndrome
	70	Juli + Phone HRV	Ovulation not designated	n=352, age 18+, cycles: 2	Mood decreased 14-3 days pre menses and was associated with lower HRV 0-3 days prior in clinically diagnosed women with depression
Menstrual cycle impacted mood but not sleep and mixed results on exercise	65	Fitbit Inspire 2	Ovulation estimated as 14 days prior to menses	n=33, 4 contraceptive users, age 24±3 yrs, cycles: 50 ovulatory	Participants with severe PMS versus no or low PMS walked less steps during the luteal phase (10,283±6,277) vs. menses (11,694±6,458)
	67	Clue app	Ovulation not designated	n=499,000, age 15-35+yrs, cycles over ≥ 12 unique months	Menstrual cycle impacted mood, behaviour, and vital signs, while exercise and sleep behaviour were more consistent

LH = Luteinising Hormone, FSH = Follicle Stimulating Hormone, PMD = Premenstrual Dysphoric Disorder combining PMDD and PMS, BBT = Basal Body Temperature, RMSSD = root mean square of successive differences, SDNN = Standard Deviation of Normal-to-Normal Intervals

Table 3: Guide to wearables, measured metrics, and associated accuracy

Metric recorded	Device	Method, sensor type if known	Accuracy	Reference, N of study, study type
Resting heart rate	Oura 2.0 and Oura	Blood pulse volume changes are detected through infrared PPG sensors in the ring; measured nocturnally every 10 minutes[119] (company website)	Versus ECG (bpm): r^2 = 0.996. Mean bias -0.63	[87] Sponsored, n=49
			Versus ECG (bpm): r2 = 0.998. Bias: -0.53, p<.001. Range: 48-66	[88] In-house, n=10
			Versus ECG (bpm): Absolute bias: 1.8 ± 4.1. Bias: overestimate 0.1 ± 4.5. Intraclass correlation: 0.85	[86] External, n=53
	WHOOP 3.0	PPG sensor in non-wake in the primary sleep episode, every 30 seconds[120]	Versus ECG (bpm): Absolute bias: −0.7 ± 0.8. Bias: -0.3 ± 0.1. Intraclass correlation: 0.99	[86] External, n=53
	Ava bracelet	PPG sensor	Versus Polar chest strap (two electrode ECG) (bpm): Mean bias: 7.8 ± 3.9. Pearson's r: 0.92, p=0.00. Mean Absolute percentage error:11.4%	[100] External, n=37
	Garmin Forerunner 245	PPG sensor	Versus ECG (bpm): Absolute bias: 5.4 ± 12.6. Bias: overestimate 5.0 ± 12.8. Intraclass correlation: 0.41	[86] External, n=53
	Apple watch S6	PPG sensor	Versus ECG (bpm): Absolute bias: 1.5 ± 1.5. Bias: 0.5 ± 2.1. Intraclass correlation: 0.96	[86] External, n=53
	Fitbit Sense	PPG sensor	Versus ECG (bpm): No significant difference in mean nocturnal heart rate mean (0.09 difference, p=0.43). Tends to overestimate when heart rate < 50 bpm by 0.51 bpm and underestimate when heart rate > 80 bpm by 0.63 bpm	[121] Systematic review with 8 papers
	SOMFIT	Pulse arterial tonometry and PPG sensor	Versus ECG (bpm): Absolute bias: 2.6 ± 6.3. Bias:2.2 ± 6.5. Intraclass correlation: 0.65	[86] External, n=53
	Huawei Band 5	PPG sensor	Limited published accuracy. Heart rate vs Polar chest strap (two electrode ECG) during elliptical exercise (n=10 college students): r = 0.981	[122] External, Huawei provided devices, n=114
			Heart rate error range ± 10 bpm	[123] Company site

HRV	Oura 2.0 and Oura	PPG sensor every five minutes throughout the night - reports RMSSD	Versus ECG (RMSSD in ms), r^2 =0.980. Mean bias 1.2	[87] Sponsored, n=49
			Versus ECG (RMSSD in ms): r2 = 0.967. Bias: -0.47 (p<.001). Range 21 to 78	[88] In-house, n=10
			Versus ECG (RMSSD in ms). Absolute accuracy: 18.9 ± 35.9. Bias: underestimate −10.2 ± 39.4. Intraclass correlation: 0.63	[86] External, n=53
			Versus ECG. RMSSD r^2 values > 0.9. Alternative HRV measures:r^2 values of SDNN, AVNN, pNN50, LF, and HF represent good fits	[124] External, n=35
	WHOOP 3.0	PPG sensor in non-wake in primary sleep episode every 30 seconds - reports RMSSD[120]	Versus ECG (RMSSD in ms): Absolute bias: 4.7 ± 3.6. Bias: −4.5 ± 3.9. Intraclass correlation: 0.99	[86] External, n=53
	Ava bracelet	PPG sensor[125] (company site) - reports LF/HF ratio	Versus actigraph with polar chest strap (2 electrode ECG) : HRV ratio had a significant low negative correlation (r: -0.28)	[100] External, n=33
	Garmin Forerunner 245	PPG sensor - reports SDRR and RMSSD	Versus ECG (RMSSD). Absolute bias:33.1 ± 39.9. Bias: - 22.4 ± 46.9. Intraclass correlation: 0.24	[86] External, n=53
	Apple watch S6	PPG sensor at unknown sampling frequency throughout sleep period	Versus ECG (SDNN in ms): Absolute bias: 22.5 ± 19.2. Bias: −9.6 ± 28.1. Intraclass correlation: 0.67	[86] External, n=53
	Fitbit Sense	PPG sensor - reports RMSSD	n/a	n/a
	SOMFIT	PPG sensor - reports RMSSD	Versus ECG (RMSSD in ms): Absolute bias: 24 ± 35. Bias:-20.5 ± 37.2. Intraclass correlation: 0.65	[86] External, n=53
	Huawei Band 5	PPG sensor - reports ln(SDNN, LF/HF)	n/a	
Skin temp	Oura (version unspecified)	Temperature sensor - Negative Temperature Coefficient sensor; measures every minute	Precision 0.13°C, every minute in the lab. Accuracy 0.36°C.Finger skin temp compared to iButton sensor in real world (r^2 >0.92) and lab (r^2 >0.99) on n=16 people for 1 week	[126] In house, (company site)
			Temperature immediately after wake up versus oral temperature, r= 0.563, p<0.01	[51] External, devices provided, n=22

	WHOOP 4.0	Temperature sensor during sleep	n/a	[127] (company site)
	Ava bracelet	Temperature sensor	n/a	[128] (company site)
	Apple watch	Two temperature sensors, one skin facing, one outside-facing to remove environmental bias	n/a	
	Garmin	Temperature sensor	n/a	[129] (company site)
	Fitbit Sense	Fitbit Sense 1/2 uses a dedicated temperature sensor. Fitbit Charge 4/5/6, Google Pixel Watch 2, Fitbit Inspire 2/3, Fitbit Luxe, and Fitbit Versa use a multi-purpose sensor	n/a	[130] (company site)
Sleep	Oura 2.0	Accelerometer + temperature sensor + PPG sensor to estimate sleep stages	Versus polysomnography: Sleep duration (mins), Accuracy : 0.86 ± 0.05. Sensitivity: 0.90 ± 0.05. Specificity: 0.54 ± 0.18	[131] External, n=36
	WHOOP 3.0 or 4.0	PPG + accelerometer	Versus polysomnography: 86% agreement for sleep vs wake, underestimated total sleep time by mean 12 min	[86] External, n=53
	Garmin Forerunner 245	Accelerometer + PPG + SpO2 sensor for 4-stages (wake, light, deep, REM)	Versus polysomnography: 89% agreement for sleep vs wake. Total sleep overestimated by mean 43.8 min	[86] External, n=53
	Ava bracelet	Accelerometer	Versus actigraphy only: Sleep duration underestimated: 8.5% mean absolute percent error. Pearson's: r=0.73, p=0.00. Mean bias: 0.18 ± 0.88 hrs	[100] External, n=33
	Apple watch S6	PPG in 5 min epochs; 3 stage categorization (wake, light, deep)	Versus polysonography: 88% agreement for sleep vs wake, overestimated total sleep with mean 39.5 min	[86] External, n=53
	Fitbit	PPG sensor + accelerometer: movement and heart-rate patterns. If no movement is detected for ~ 1 hour the user is assumed asleep[132]	Versus actigraphy: total sleep time overestimated with mean absolute error of 36.6% (56 minutes)	[99] External, n=30
			Versus polysomnography: Sleep duration: Accuracy: 0.84 ± 0.07. Sensitivity: 0.89 ± 0.09. Specificity: 0.49 ± 0.18	[131] External, n=36

			Versus polysonography: Fitbit tends to overestimate sleep duration (7-67 mins), overestimate sleep efficiency (2-15%) and underestimate wake time (6-44min). No difference in sleep onset latency. Sleep-staging models identified sleep epochs with greater sensitivity (0.95-0.96) and specificity (0.58-0.69) than non sleep-staging models (0.87-0.99 and 0.1-0.52) respectively. Models using HRV and movement performed better than using only movement	[133] Systematic review, 8 papers with quantitative data
	SOMFIT	Algorithms using eye movement and electroencephalogram forehead data	Versus polysomnography: 89.3% accuracy for wake v sleep, 80-95% accuracy for 4 sleep stages + wake	[134] Sponsored, n=110
	Huawei Band GT	Uses accelerometry, HR, HRV to estimate sleep stages[135] (company site)	Versus actigraphy for sleep time assessment: Intraclass correlation: 0.25 (p<.001). Mean absolute percentage error: 23.29%	[136] External, n = 102
Respiratory rate	Oura 2.0	Average nocturnal rate via increase/ decrease in heart rate with breath in/out	Versus ECG-derived respiratory metric: Average 0.71 breaths/min over a night; correlation = 0.96	[137] Internal, n = 43
	WHOOP 2.0	Calculates median respiratory rate during sleep via increase and decrease in heart rate with breath in and out[138] (Company site)	No significant difference between respiratory inductive plethysmography (breaths/min) (15.6 ± 1.7) and WHOOP (15.7 ± 1.7) with bias error 0.1 (1.8%) , precision error 1.0 (6.7%)	[94] External, n=32 (21 female)
	Garmin Forerunner 245	Calculates respiratory rate from raw heart rate data via increase/decrease in heart rate with breath in/out	n/a	n/a
	Ava bracelet	Calculates breathing rate via increase and decrease in heart rate with breath in and out respectively	Versus chest strap overnight, mean absolute errors of 0.9 breaths/min	[139] External, n = 7
	Apple watch	Accelerometer-based estimate of nocturnal breaths per minute	n/a	n/a
	Fitbit	Optical heart rate sensor tracks change in heart rate intervals for still/sleep periods>3 hours[140] (company site)	Versus polysomnography: Root mean squared error = 0.658 breaths/min. Mean absolute error = 0.46 breaths/min. Mean absolute percentage error = 3%	[141] Internal, n= 28

PPG= photoplethysmography, ECG = electrocardiogram, RMSSD = root mean square of successive differences, SDNN = Standard Deviation of Normal-to-Normal Intervals, AVNN=Average of the Normal-to-Normal (NN) intervals, pNN50 = percentage of Normal-to-Normal (NN) intervals that differ by more than 50 milliseconds from the preceding interval, LF = low frequency, HF=high frequency, SDRR = standard deviation between consecutive R-wave

9. References

1. Tanaka, E. *et al.* Burden of menstrual symptoms in Japanese women: results from a survey-based study. *J Med Econ* **16**, 1255–1266 (2013).

2. Rapkin, A. J. & Winer, S. A. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. *Expert Rev Pharmacoecon Outcomes Res* **9**, 157–170 (2009).

3. Halbreich, U., Borenstein, J., Pearlstein, T. & Kahn, L. S. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). *Psychoneuroendocrinology* **28 Suppl 3**, 1–23 (2003).

4. Schoep, M. E. *et al.* Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. *BMJ Open* **9**, e026186 (2019).

5. Solli, G. S., Sandbakk, S. B., Noordhof, D. A., Ihalainen, J. K. & Sandbakk. Changes in Self-Reported Physical Fitness, Performance, and Side Effects Across the Phases of the Menstrual Cycle Among Competitive Endurance Athletes. *Int J Sports Physiol Perform* **15**, 1324–1333 (2020).

6. Armour, M., Parry, K. A., Steel, K. & Smith, C. A. Australian female athlete perceptions of the challenges associated with training and competing when menstrual symptoms are present. *Int. J. Sports Sci. Coach.* **15**, 316–323 (2020).

7. Findlay, R. J., Macrae, E. H. R., Whyte, I. Y., Easton, C. & Forrest Née Whyte, L. J. How the menstrual cycle and menstruation affect sporting performance: experiences and perceptions of elite female rugby players. *Br J Sports Med* **54**, 1108–1113 (2020).

8. Faubion, S. S. *et al.* Impact of Menopause Symptoms on Women in the Workplace. *Mayo Clin Proc* **98**, 833–845 (2023).

9. Forman, R. G., Chapman, M. C. & Steptoe, P. C. The effect of endogenous progesterone

on basal body temperature in stimulated ovarian cycles. *Hum Reprod* **2**, 631–634 (1987).

10. Stachenfeld, N. S., Silva, C. & Keefe, D. L. Estrogen modifies the temperature effects of progesterone. *J Appl Physiol (1985)* **88**, 1643–1649 (2000).

11. Israel, L. S. & Schneller, O. The thermogenic property of progesterone. *Obstet. Gynecol. Surv.* **5**, 532–533 (1950).

12. Baker, F. C., Siboza, F. & Fuller, A. Temperature regulation in women: Effects of the menstrual cycle. *Temperature (Austin)* **7**, 226–262 (2020).

13. Behan, M. & Wenninger, J. M. Sex steroidal hormones and respiratory control. *Respir Physiol Neurobiol* **164**, 213–221 (2008).

14. Haggerty, C. L., Ness, R. B., Kelsey, S. & Waterer, G. W. The impact of estrogen and progesterone on asthma. *Ann Allergy Asthma Immunol* **90**, 284–91; quiz 291–3, 347 (2003).

15. Blaser, B. L., Weymar, M. & Wendt, J. Premenstrual syndrome is associated with differences in heart rate variability and attentional control throughout the menstrual cycle: A pilot study. *Int J Psychophysiol* **204**, 112374 (2024).

16. Matsumoto, T., Ushiroyama, T., Kimura, T., Hayashi, T. & Moritani, T. Altered autonomic nervous system activity as a potential etiological factor of premenstrual syndrome and premenstrual dysphoric disorder. *Biopsychosoc Med* **1**, 24 (2007).

17. Baker, F. C., Colrain, I. M. & Trinder, J. Reduced parasympathetic activity during sleep in the symptomatic phase of severe premenstrual syndrome. *J Psychosom Res* **65**, 13–22 (2008).

18. Landén, M. *et al.* Heart rate variability in premenstrual dysphoric disorder. *Psychoneuroendocrinology* **29**, 733–740 (2004).

19. Pichon, A., Jackman, K. B., Winkler, I. T., Bobel, C. & Elhadad, N. The messiness of the menstruator: assessing personas and functionalities of menstrual tracking apps. *J. Am. Med. Inform. Assoc.* **29**, 385–399 (2022).

20. Zvarikova, K., Machova, V. & Pera, A. Menstrual cycle tracking apps, fertility and reproductive data, and mobile health care management. *J. Res. Gend. Stud.* **12**, 84 (2022).

21. Schantz, J. S., Fernandez, C. S. P. & Anne Marie, Z. J. Menstrual Cycle Tracking Applications and the Potential for Epidemiological Research: A Comprehensive Review of the Literature. *Curr Epidemiol Rep* **8**, 9–19 (2021).

22. Huhn, S. *et al.* The Impact of Wearable Technologies in Health Research: Scoping Review. *JMIR Mhealth Uhealth* **10**, e34384 (2022).

23. Fitzpatrick, M. B. & Thakor, A. S. Advances in Precision Health and Emerging Diagnostics for Women. *J. Clin. Med. Res.* **8**, (2019).

24. Lyzwinski, L., Elgendi, M. & Menon, C. Innovative Approaches to Menstruation and Fertility Tracking Using Wearable Reproductive Health Technology: Systematic Review. *J. Med. Internet Res.* **26**, e45139 (2024).

25. Kalampalikis, A., Chatziioannou, S. S., Protopapas, A., Gerakini, A. M. & Michala, L. mHealth and its application in menstrual related issues: a systematic review. *Eur. J. Contracept. Reprod. Health Care* **27**, 53–60 (2022).

26. Saugar, E. E. *et al.* Factors used by mobile applications to predict female fertility status and their reported effectiveness: A scoping review. *Cureus* **15**, e48847 (2023).

27. Haddaway, N. R., Page, M. J., Pritchard, C. C. & McGuinness, L. A. : An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst Rev* **18**, e1230 (2022).

28. Rosen Vollmar, A. K., Mahalingaiah, S. & Jukic, A. M. The menstrual cycle as a vital sign: a comprehensive review. *F S Rev.* **6**, 100081 (2025).

29. Soumpasis, I., Grace, B. & Johnson, S. Real-life insights on menstrual cycles and ovulation using big data. *Hum Reprod Open* (2020).

30. Grieger, J. A. & Norman, R. J. Menstrual Cycle Length and Patterns in a Global Cohort of Women Using a Mobile Phone App: Retrospective Cohort Study. *J Med Internet Res* **22**,

e17109 (2020).

31. Nguyen, B. T. *et al.* Detecting variations in ovulation and menstruation during the COVID-19 pandemic, using real-world mobile app data. *PLoS One* **16**, e0258314 (2021).

32. Li, K. *et al.* Characterizing physiological and symptomatic variation in menstrual cycles using self-tracked mobile-health data. *NPJ Digit Med* **3**, 79 (2020).

33. Roffler, A., Fleddermann, M.-T., de Haan, H., Krüger, K. & Zentgraf, K. Menstrual cycle tracking in professional volleyball athletes. *Front Sports Act Living* **6**, 1408711 (2024).

34. Hurst, B. S., Davies, K., Milnes, R. C., Knowles, T. G. & Pirrie, A. Novel Technique for Confirmation of the Day of Ovulation and Prediction of Ovulation in Subsequent Cycles Using a Skin-Worn Sensor in a Population With Ovulatory Dysfunction: A Side-by-Side Comparison With Existing Basal Body Temperature Algorithm and Vaginal Core Body Temperature Algorithm. *Front Bioeng Biotechnol* **10**, 807139 (2022).

35. American College of Obstetricians and Gynecologists. Abnormal Uterine Bleeding. https://www.acog.org/womens-health/faqs/abnormal-uterine-bleeding (2023).

36. Jasinski, S. R., Presby, D. M., Grosicki, G. J., Capodilupo, E. R. & Lee, V. H. A Novel method for quantifying fluctuations in wearable derived daily cardiovascular parameters across the menstrual cycle. *NPJ Digit Med* **7**, 373 (2024).

37. The Practice Committee of the American Society for Reproductive Medicine. The clinical relevance of luteal phase deficiency: a committee opinion. *Fertil. Steril.* **98**, 112–1117.

38. Crawford, N. M., Pritchard, D. A., Herring, A. H. & Steiner, A. Z. Prospective evaluation of luteal phase length and natural fertility. *Fertil Steril* **107**, 749–755 (2017).

39. Charles R. B. Beckmann, William Herbert, Douglas Laube, Frank Ling, Roger Smith. *Obstetrics and Gynecology*. 66–67 (Lippincott Williams and Wilkins, Philadelphia, PA, 2013).

40. Yu, J.-L. *et al.* Tracking of menstrual cycles and prediction of the fertile window via measurements of basal body temperature and heart rate as well as machine-learning

algorithms. *Reprod Biol Endocrinol* **20**, 118 (2022).

41. Baird, D. D. *et al.* Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. *Epidemiology* **6**, 547–550 (1995).

42. Lenton, E. A., Landgren, B. M., Sexton, L. & Harper, R. Normal variation in the length of the follicular phase of the menstrual cycle: effect of chronological age. *Br J Obstet Gynaecol* **91**, 681–684 (1984).

43. Bull, J. R. *et al.* Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit Med* **2**, 83 (2019).

44. Soumpasis, I., Grace, B. & Johnson, S. Real-life insights on menstrual cycles and ovulation using big data. *Hum Reprod Open* (2020).

45. Grieger, J. A. & Norman, R. J. Menstrual Cycle Length and Patterns in a Global Cohort of Women Using a Mobile Phone App: Retrospective Cohort Study. *J Med Internet Res* **22**, e17109 (2020).

46. Cunningham, A. C. *et al.* Chronicling menstrual cycle patterns across the reproductive lifespan with real-world data. *Sci Rep* **14**, 10172 (2024).

47. Li, H. *et al.* Menstrual cycle length variation by demographic characteristics from the Apple Women's Health Study. *NPJ Digit. Med.* **6**, 100 (2023).

48. Zhang, C. Y. *et al.* Abnormal uterine bleeding patterns determined through menstrual tracking among participants in the Apple Women's Health Study. *Am J Obstet Gynecol* **228**, 213.e1–213.e22 (2023).

49. Goodale, B. M. *et al.* Wearable Sensors Reveal Menses-Driven Changes in Physiology and Enable Prediction of the Fertile Window: Observational Study. *J Med Internet Res* **21**, e13404 (2019).

50. Alzueta, E. *et al.* Tracking Sleep, Temperature, Heart Rate, and Daily Symptoms Across the Menstrual Cycle with the Oura Ring in Healthy Women. *Int J Womens Health* **14**, 491–503 (2022).

51. Maijala, A., Kinnunen, H., Koskimäki, H., Jämsä, T. & Kangas, M. Nocturnal finger skin temperature in menstrual cycle tracking: ambulatory pilot study using a wearable Oura ring. *BMC Women's Health* **19**, 150 (2019).

52. Shilaih, M. *et al.* Modern fertility awareness methods: wrist wearables capture the changes in temperature associated with the menstrual cycle. *Biosci Rep* **38**, (2018).

53. Zhu, T. Y. *et al.* The Accuracy of Wrist Skin Temperature in Detecting Ovulation Compared to Basal Body Temperature: Prospective Comparative Diagnostic Accuracy Study. *J Med Internet Res* **23**, e20710 (2021).

54. Namie, T. *et al.* Menstrual variations of sleep-wake rhythms in healthy women. *Sleep Biol Rhythms* **23**, 5–12 (2025).

55. Murayama, Y., Tang, Z., Saito, K., Nakano, T. & Mitsui, M. Monitoring basal body temperature rhythm: Abdominal skin temperature measurements taken during sleep as simpler alternative. *IEEE Access* **12**, 182374–182385 (2024).

56. Lin, G. *et al.* Understanding wrist skin temperature changes to hormone variations across the menstrual cycle. *NPJ Women's Health* **2**, 35 (2024).

57. Marshall, J. A field trial of the basal-body-temperature method of regulating births. *Lancet* **2**, 8–10 (1968).

58. Martinez, A. R. *et al.* The reliability, acceptability and applications of basal body temperature (BBT) records in the diagnosis and treatment of infertility. *Eur J Obstet Gynecol Reprod Biol* **47**, 121–127 (1992).

59. McKinley, P. S. *et al.* The impact of menstrual cycle phase on cardiac autonomic regulation. *Psychophysiology* **46**, 904–911 (2009).

60. Baker, F. C. & Lee, K. A. Menstrual Cycle Effects on Sleep. *Sleep Med Clin* **13**, 283–294 (2018).

61. Sato, N., Miyake, S., Akatsu, J. & Kumashiro, M. Power spectral analysis of heart rate variability in healthy young women during the normal menstrual cycle. *Psychosom Med* **57**,

331–335 (1995).

62. Leicht, A. S., Hirning, D. A. & Allen, G. D. Heart rate variability and endogenous sex hormones during the menstrual cycle in young women. *Exp Physiol* **88**, 441–446 (2003).

63. Sims, S. T., Ware, L. & Capodilupo, E. R. Patterns of endogenous and exogenous ovarian hormone modulation on recovery metrics across the menstrual cycle. *BMJ Open Sport Exerc Med* **7**, e001047 (2021).

64. Shilaih, M., Clerck, V. de, Falco, L., Kübler, F. & Leeners, B. Pulse Rate Measurement During Sleep Using Wearable Sensors, and its Correlation with the Menstrual Cycle Phases, A Prospective Observational Study. *Sci Rep* **7**, 1294 (2017).

65. Lang, A.-L. *et al.* Feasibility Study on Menstrual Cycles With Fitbit Device (FEMFIT): Prospective Observational Cohort Study. *JMIR Mhealth Uhealth* **12**, e50135 (2024).

66. Altini, M. & Plews, D. What Is behind Changes in Resting Heart Rate and Heart Rate Variability? A Large-Scale Analysis of Longitudinal Measurements Acquired in Free-Living. *Sensors (Basel)* **21**, (2021).

67. Pierson, E., Althoff, T., Thomas, D., Hillard, P. & Leskovec, J. Daily, weekly, seasonal and menstrual cycles in women's mood, behaviour and vital signs. *Nat Hum Behav* **5**, 716–725 (2021).

68. Godbole, G., Joshi, A. R. & Vaidya, S. M. Effect of female sex hormones on cardiorespiratory parameters. *J Family Med Prim Care* **5**, 822–824 (2016).

69. Pan, Q. *et al.* Wearable-measured heart rate variability and premenstrual disorder symptoms across menstrual cycle. *medRxiv* (2024) doi:10.1101/2024.10.27.24316196.

70. Delray, K., Lewis, G. & Hayes, J. F. Tracking mood symptoms across the menstrual cycle in women with depression using ecological momentary assessment and heart rate variability. *BMJ Ment Health* **28**, (2025).

71. Van Reen, E. & Kiesner, J. Individual differences in self-reported difficulty sleeping across the menstrual cycle. *Arch Womens Ment Health* **19**, 599–608 (2016).

72. Baker, F. C. & Driver, H. S. Self-reported sleep across the menstrual cycle in young, healthy women. *J Psychosom Res* **56**, 239–243 (2004).

73. Baker, F. C. & Driver, H. S. Circadian rhythms, sleep, and the menstrual cycle. *Sleep Med.* **8**, 613–622 (2007).

74. Zheng, H. *et al.* Actigraphy-defined measures of sleep and movement across the menstrual cycle in midlife menstruating women: Study of Women's Health Across the Nation Sleep Study. *Menopause* **22**, 66–74 (2015).

75. Li, D. X., Romans, S., De Souza, M. J., Murray, B. & Einstein, G. Actigraphic and self-reported sleep quality in women: associations with ovarian hormones and mood. *Sleep Med* **16**, 1217–1224 (2015).

76. Markovic, A. *et al.* Physiological Response to the COVID-19 Vaccine: Insights From a Prospective, Randomized, Single-Blinded, Crossover Trial. *J Med Internet Res* **26**, e51120 (2024).

77. Costeira, R. *et al.* Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study. *PLoS One* **16**, e0257051 (2021).

78. Germini, F. *et al.* Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature. *J Med Internet Res* **24**, e30791 (2022).

79. Shin, G. *et al.* Wearable activity trackers, accuracy, adoption, acceptance and health impact: A systematic literature review. *J Biomed Inform* **93**, 103153 (2019).

80. Fuller, D. *et al.* Reliability and Validity of Commercially Available Wearable Devices for Measuring Steps, Energy Expenditure, and Heart Rate: Systematic Review. *JMIR Mhealth Uhealth* **8**, e18694 (2020).

81. Molnar, G. W. Body temperatures during menopausal hot flashes. *J Appl Physiol* **38**, 499–503 (1975).

82. Freedman, R. R. & Woodward, S. Core body temperature during menopausal hot flushes. *Fertil. Steril.* **65**, 1141–1144 (1996).

83. Hasselberg, M. J., McMahon, J. & Parker, K. The validity, reliability, and utility of the iButton® for measurement of body temperature circadian rhythms in sleep/wake research. *Sleep Med* **14**, 5–11 (2013).

84. Burgess, G. E., 3rd, Cooper, J. R., Marino, R. J. & Peuler, M. J. Continuous monitoring of skin temperature using a liquid-crystal thermometer during anesthesia. *South Med J* **71**, 516–518 (1978).

85. Kryder, C. How Accurate Is Oura's Temperature Data? *ouraring.com* https://ouraring.com/blog/temperature-validated-accurate/ (2020).

86. Miller, D. J., Sargent, C. & Roach, G. D. A Validation of Six Wearable Devices for Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults. *Sensors (Basel)* **22**, (2022).

87. Kinnunen, H., Rantanen, A., Kenttä, T. & Koskimäki, H. Feasible assessment of recovery and cardiovascular health: accuracy of nocturnal HR and HRV assessed via ring PPG in comparison to medical grade ECG. *Physiol Meas* **41** (2020).

88. Kinnunen, H. O. & Koskimäki, H. 0312 the HRV of the ring - comparison of nocturnal HR and HRV between A commercially available wearable ring and ECG. *Sleep* **41**, A120–A120 (2018).

89. Boonya-Ananta, T. *et al.* Synthetic photoplethysmography (PPG) of the radial artery through parallelized Monte Carlo and its correlation to body mass index (BMI). *Sci Rep* **11**, 2570 (2021).

90. Pasadyn, S. R. *et al.* Accuracy of commercially available heart rate monitors in athletes: a prospective study. *Cardiovasc Diagn Ther* **9**, 379–385 (2019).

91. Schweizer, T. & Gilgen-Ammann, R. Wrist-Worn and Arm-Worn Wearables for Monitoring Heart Rate During Sedentary and Light-to-Vigorous Physical Activities: Device Validation Study. *JMIR Cardio* **9**, e67110 (2025).

92. Zhu, K. *et al.* Vision-Based Heart and Respiratory Rate Monitoring During Sleep - A

Validation Study for the Population at Risk of Sleep Apnea. *IEEE J Transl Eng Health Med* **7**, 1900708 (2019).

93. Hayashi, K., Kawashima, T. & Suzuki, Y. Effect of menstrual cycle phase on the ventilatory response to rising body temperature during exercise. *J Appl Physiol (1985)* **113**, 237–245 (2012).

94. Berryhill, S. *et al.* Effect of wearables on sleep in healthy individuals: a randomized crossover trial and validation study. *J Clin Sleep Med* **16**, 775–783 (2020).

95. Schmalenberger, K. M. *et al.* A Systematic Review and Meta-Analysis of Within-Person Changes in Cardiac Vagal Activity across the Menstrual Cycle: Implications for Female Health and Future Studies. *J Clin Med* **8**, (2019).

96. Brar, T. K., Singh, K. D. & Kumar, A. Effect of Different Phases of Menstrual Cycle on Heart Rate Variability (HRV). *J Clin Diagn Res* **9**, CC01–4 (2015).

97. Voronova, N. V., Meigal, A. Y., Yelaeva, L. E. & Kuzmina, G. I. Heart rate variability in women during various seasons and phases of the menstrual cycle. *Èkol. čeloveka* **22**, 20–26 (2015).

98. Asgari Mehrabadi, M. *et al.* Sleep Tracking of a Commercially Available Smart Ring and Smartwatch Against Medical-Grade Actigraphy in Everyday Settings: Instrument Validation Study. *JMIR Mhealth Uhealth* **8**, e20465 (2020).

99. Kubala, A. G. *et al.* Field-based Measurement of Sleep: Agreement between Six Commercial Activity Monitors and a Validated Accelerometer. *Behav Sleep Med* **18**, 637–652 (2020).

100. Nulty, A. K., Chen, E. & Thompson, A. L. The Ava bracelet for collection of fertility and pregnancy data in free-living conditions: An exploratory validity and acceptability study. *Digit Health* **8**, 20552076221084461 (2022).

101. The Department for Health and Social Care (DHSC). Results of the 'Women's Health – Let's talk about it' survey'. *gov.uk* https://www.gov.uk/government/calls-for-

evidence/womens-health-strategy-call-for-evidence/outcome/results-of-the-womens-health-lets-talk-about-it-survey (2022).

102. Hudson, N. The missed disease? Endometriosis as an example of 'undone science'. *Reprod. Biomed. Soc. Online* **14**, 20–27 (2022).

103. Meuleman, C. *et al.* High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. *Fertil. Steril.* **92**, 68–74 (2009).

104. Mosconi, L. *et al.* Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. *Sci. Rep.* **11**, 10867 (2021).

105. Teixeira, A. L., Ramos, P. S., Vianna, L. C. & Ricardo, D. R. Heart rate variability across the menstrual cycle in young women taking oral contraceptives. *Psychophysiology* **52**, 1451–1455 (2015).

106. Nassaralla, C. L. *et al.* Characteristics of the menstrual cycle after discontinuation of oral contraceptives. *J Womens Health (Larchmt)* **20**, 169–177 (2011).

107. Blaser, B. L., Weymar, M. & Wendt, J. Alleviating premenstrual symptoms with smartphone-based heart rate variability biofeedback training: a pilot study. *Front Digit Health* **6**, 1337667 (2024).

108. Vidal, C. The ethics of menstrual tracking applications. *Nat Hum Behav* **8**, 2076 (2024).

109. Alfawzan, N., Christen, M., Spitale, G. & Biller-Andorno, N. Privacy, Data Sharing, and Data Security Policies of Women's mHealth Apps: Scoping Review and Content Analysis. *JMIR Mhealth Uhealth* **10**, e33735 (2022).

110. Dong, Z., Wang, L., Xie, H., Xu, G. & Wang, H. Privacy analysis of period tracking mobile apps in the post-roe v. Wade era. in *Proceedings of the 37th IEEE/ACM International Conference on Automated Software Engineering* 1–6 (ACM, New York, NY, USA, 2022).

111. Symul, L., Wac, K., Hillard, P. & Salathé, M. Assessment of menstrual health status and evolution through mobile apps for fertility awareness. *NPJ Digit Med* **2**, 64 (2019).

112. Sohda, S., Suzuki, K. & Igari, I. Relationship Between the Menstrual Cycle and Timing of

Ovulation Revealed by New Protocols: Analysis of Data from a Self-Tracking Health App. *J Med Internet Res* **19**, e391 (2017).

113. Bradley, D. *et al.* Time to conception and the menstrual cycle: an observational study of fertility app users who conceived. *Hum Fertil (Camb)* **24**, 267–275 (2021).

114. Ramaiyer, M. *et al.* The association of COVID-19 vaccination and menstrual health: A period-tracking app-based cohort study. *Vaccine X* **19**, 100501 (2024).

115. Alvergne, A., Vlajic Wheeler, M. & Högqvist Tabor, V. Do sexually transmitted infections exacerbate negative premenstrual symptoms? Insights from digital health. *Evol Med Public Health* **2018**, 138–150 (2018).

116. Wegrzynowicz, A. K. *et al.* Complete Cycle Mapping Using a Quantitative At-Home Hormone Monitoring System in Prediction of Fertile Days, Confirmation of Ovulation, and Screening for Ovulation Issues Preventing Conception. *Medicina (Kaunas)* **58**, (2022).

117. Faust, L. *et al.* Findings from a mobile application-based cohort are consistent with established knowledge of the menstrual cycle, fertile window, and conception. *Fertil Steril* **112**, 450–457.e3 (2019).

118. Harley, K. G., Watson, A., Robertson, S., Vitzthum, V. J. & Shea, A. Menstrual Cycle Characteristics of U. S. Adolescents According to Gynecologic Age and Age at Menarche. *J Pediatr Adolesc Gynecol* **37**, 419–425 (2024).

119. OURA. Resting Heart Rate. *Ouraring.com* https://support.ouraring.com/hc/en-us/articles/360025588793-Resting-Heart-Rate.

120. Jasinski, S. R., Rowan, S., Presby, D. M., Claydon, E. A. & Capodilupo, E. R. Wearable-derived maternal heart rate variability as a novel digital biomarker of preterm birth. *PLoS One* **19**, e0295899 (2024).

121. Haghayegh, S., Khoshnevis, S., Smolensky, M. H. & Diller, K. R. Accuracy of PurePulse photoplethysmography technology of Fitbit Charge 2 for assessment of heart rate during sleep. *Chronobiol Int* **36**, 927–933 (2019).

122. Ding, J., Hong, W. & and Li, H. Comparison of the accuracy of three wrist-worn tracking devices when measuring heart rate during aerobic exercise. in *ISBS Proceedings Archive* (https://commons.nmu.edu/isbs/vol40/iss1/35, 2022).

123. Heart rate measurements on my HUAWEI wearable device are inaccurate. *HUAWEI* https://consumer.huawei.com/en/support/content/en-us00733859/.

124. Cao, R. *et al.* Accuracy Assessment of Oura Ring Nocturnal Heart Rate and Heart Rate Variability in Comparison With Electrocardiography in Time and Frequency Domains: Comprehensive Analysis. *J Med Internet Res* **24**, e27487 (2022).

125. Meisel, L. What Your Ava Data Means. *Avawomen.com* https://www.avawomen.com/avaworld/ava-data-means/ (2017).

126. Ōura Health Oy. How Accurate Is Oura's Temperature Data? *Ouraring.com* https://ouraring.com/blog/temperature-validated-accurate/.

127. Meserve, C. New WHOOP 4.0 Metric: Skin Temperature. *Whoop.com* https://www.whoop.com/de/en/thelocker/how-whoop-tracks-skin-temperature/ (2021).

128. Gobinath, A. What Sensors Are On the Ava Bracelet? *Avawomen.com* https://www.avawomen.com/avaworld/sensors-ava-bracelet/ (2018).

129. Garmin Ltd. What Is the Skin Temperature Feature in Garmin Connect? *support.garmin.com* https://support.garmin.com/en-US/?faq=RDXq6E5Iaq9rD1I1kTObf6.

130. Google. How can Fitbit help me track my temperature? *Fitbit help center* https://support.google.com/fitbit/answer/14237207?sjid=13360756588868122580-NC.

131. Grandner, M. A. *et al.* Performance of a multisensor smart ring to evaluate sleep: in-lab and home-based evaluation of generalized and personalized algorithms. *Sleep* **46**, (2023).

132. Google. What should I know about Fitbit sleep stages? *Fitbit help center* https://support.google.com/fitbit/answer/14236712#zippy=%2Chow-does-my-fitbit-device-automatically-detect-my-sleep-stages.

133. Haghayegh, S., Khoshnevis, S., Smolensky, M. H., Diller, K. R. & Castriotta, R. J. Accuracy

of Wristband Fitbit Models in Assessing Sleep: Systematic Review and Meta-Analysis. *J. Med. Internet Res.* **21**, e16273 (2019).

134. McMahon, M. *et al.* Performance Investigation of Somfit Sleep Staging Algorithm. *Nat Sci Sleep* **16**, 1027–1043 (2024).

135. Huawei. HUAWEI Band 8 Principles behind sleep tracking. *Huawei* https://consumer.huawei.com/en/support/content/en-us15963854/.

136. Mei, L., He, Z. & Hu, L. Accuracy of the Huawei GT2 Smartwatch for Measuring Physical Activity and Sleep Among Adults During Daily Life: Instrument Validation Study. *JMIR Form Res* **8**, e59521 (2024).

137. Oura Team. How Accurate Is Oura's Respiratory Rate? https://ouraring.com/blog/how-accurate-is-ouras-respiratory-rate/? (2020).

138. Capodilupo, E. Understanding Respiratory Rate: What it Is, What's Normal & Why You Should Track It. *Whoop.com* https://www.whoop.com/qa/en/thelocker/what-is-respiratory-rate-normal/ (2021).

139. Renevey, P. *et al.* Respiratory and cardiac monitoring at night using a wrist wearable optical system. *arXiv [eess.SP]* (2017).

140. Google. How do I track breathing rate in the Fitbit app? *Fitbit help center* https://support.google.com/fitbit/answer/14237113?sjid=13360756588868122580-NC.

141. Natarajan, A. *et al.* Measurement of respiratory rate using wearable devices and applications to COVID-19 detection. *NPJ Digit. Med.* **4**, 136 (2021).